기본 정보
- CAS
3344-18-1- 표준 SMILES
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2]- InChIKey
PLSARIKBYIPYPF-UHFFFAOYSA-H- 분자식
- C12H10Mg3O14
- 평균 분자량
- 451.12 g/mol
- 단동위원소 질량
- 449.9621801
이름 및 식별자
- 우선 이름
- Trimagnesium dicitrate
- IUPAC
- trimagnesium bis(2-hydroxypropane-1,2,3-tricarboxylate)
- 영어명
- Trimagnesium dicitrate
- 분자식
- C6H10MgO7
- 분자량
- 218.44
이름 및 동의어
Trimagnesium dicitrateMAGNESIUM CITRATE3344-18-1Trimagnesium citratemagnesium dicitrateCitric acid, magnesium salt (2:3)CITRAMAGRHO26O1T9V1,2,3-Propanetricarboxylic acid, 2-hydroxy-, magnesium salt (2:3)NSC-83517CHEBI:131391DTXSID601015151
이름 더 보기
Magnesium citrate hydrateTectlolMagcorolNsc83517Magcorol Pmagnesiumcitrate16%MAGNESIUM DI CITRATEriMagnesiuM dicitrate
CHEBI:131389CitromaGadavytMagcitCitroMagSaline LaxativeMg citrateMagesium Citrate
데이터베이스 식별자
- CAS
3344-18-1- PubChem CID
- 6099959
- DTXSID
DTXSID601015151- ChEMBL
CHEMBL3989480- ChEBI
CHEBI:131391- UNII
- RHO26O1T9V
- EC Number
- 222-093-9
물성
구조 계산 물성
- 극성 표면적
- 281 Ų
- 수소 결합 공여자 수
- 2
- 수소 결합 수용자 수
- 14
- 회전 가능 결합 수
- 4
- 무거운 원자 수
- 29
- 형식 전하
- 0
- 복잡도
- 211
실험 및 물리화학적 성질
SolubilityPartially soluble in cold water
Melting Point184
물리화학적 성질
- 녹는점
- 184 °C · 184 °C
- 저장 조건
- Sealed in dry,Room Temperature
- 용해도
- 물에 용해되고 에탄올에는 거의 용해되지 않습니다(96%). 묽은 염산에 녹는다.
- 물리적 상태
- 가루
- 색상
- 흰색에서 황백색까지
- 냄새
- 냄새 없는
- 수용성
- 물에 약간 용해됩니다.
- Merck
- 14 · 14,5663
- 주요 응용
- 의약품(소분자)
- InChI
- InChI=1S/C6H8O7.Mg.2H/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;
- InChIKey
- RCMPDQYZJPTTFC-UHFFFAOYSA-N
- SMILES
- C(O)(C(=O)O)(CC(=O)O)CC(=O)O.[Mg]
- LogP
- -1.721 · -1.721 (est)
화학적 성질
White or slightly yellow granules powder
안전 및 규제
GHS 분류
GHS Classification
This chemical does not meet GHS hazard criteria for 98.7% (74 of 75) of all reports.
Not Classified；Reported as not meeting GHS hazard criteria by 74 of 75 companies (only 1.3% companies provided GHS information). For more detailed information, please visit ECHA C&L website.
Aggregated GHS information provided per 75 reports by companies from 2 notifications to the ECHA C&L Inventory.；Reported as not meeting GHS hazard criteria per 74 of 75 reports by companies.；There is 1 notification provided by 1 of 75 reports by companies with hazard statement code(s).；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
유해성 정보
Regulatory Information
Chemical: 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, magnesium salt(2:3)
Regulation (EC) No 1331/2008
Status: Active Update: 28-09-2021 https://echa.europa.eu/registration-dossier/-/registered-dossier/10972
Magnesium Citrate: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, magnesium salt(2:3): Human health tier I assessment
Hazard Classes and CategoriesNot Classified
독성 정보
Toxicity SummarySafe in the present practices of use and concentration. Ingredient, concentration, and use information are available in documents discoverable at https://cir-reports.cir-safety.org
Effects During Pregnancy and Lactation
화학 및 산업
약리 정보
ATC Code
B - Blood and blood forming organs；B05 - Blood substitutes and perfusion solutions；B05C - Irrigating solutions；B05CB - Salt solutions；B05CB03 - Magnesium citrate
A - Alimentary tract and metabolism；A06 - Drugs for constipation；A06A - Drugs for constipation；A06AD - Osmotically acting laxatives；A06AD19 - Magnesium citrate
A - Alimentary tract and metabolism；A12 - Mineral supplements；A12C - Other mineral supplements；A12CC - Magnesium；A12CC04 - Magnesium citrate
QA - Alimentary tract and metabolism；QA06 - Drugs for constipation；QA06A - Drugs for constipation；QA06AD - Osmotically acting laxatives；QA06AD19 - Magnesium citrate
QB - Blood and blood forming organs；QB05 - Blood substitutes and perfusion solutions；QB05C - Irrigating solutions；QB05CB - Salt solutions；QB05CB03 - Magnesium citrate
QA - Alimentary tract and metabolism；QA12 - Mineral supplements；QA12C - Other mineral supplements；QA12CC - Magnesium；QA12CC04 - Magnesium citrate
Protein BindingMagnesium, once ionized, is highly bound to plasma proteins and it can represent even 90% of the magnesium found in blood plasma.
Pharmacodynamics
The onset of action can be as early as 30 minutes after administration with a mean onset time of approximately 2 hours and a maximum action of 4 hours. The effect of magnesium citrate is highly dependent on the individual's hydration status.
Mechanism of ActionIt mainly works through its property of high osmolality which will draw large amounts of fluid into the colonic lumen. There is also a possible stimulation of fluid excretion by cholecystokinin release and activation of muscle peristalsis.
Biological Half-LifeThe study of the half-life of magnesium citrate is very difficult due to the half-life of the available isotopes for magnesium.
FDA Pharmacological Classification
MAGESIUM CITRATE
Osmotic Activity [MoA]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]; Calculi Dissolution Agent [EPC]; Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]; Increased Large Intestinal Motility [PE]; Osmotic Laxative [EPC]; Magnesium Ion Exchange Activity [MoA]; Inhibition Small Intestine Fluid/Electrolyte Absorption [PE]
관련 반응
8건
화합물 노트
불러오는 중…